S699 GLP-1 receptor agonists are associated with decreased esophageal cancer risk in type 2 diabetes patients compared to other anti-diabetic therapy

Authors

Khaled Alsabbagh Alchirazi, Advocate Health - MidwestFollow
Ahmed El Telbany
Saqr Alsakarneh
Tarek Sawas

Recommended Citation

Alchirazi K, El Telbany A, Alsakarneh S, Sawas T. S699 GLP-1 Receptor Agonists Are Associated With Decreased Esophageal Cancer Risk in Type 2 Diabetes Patients Compared to Other Anti-Diabetic Therapy. The American Journal of Gastroenterology. 2024; 119 (10S): S484-S485. doi: 10.14309/01.ajg.0001032164.05931.aa

Affiliations

Aurora Healthcare, Brookfield, WI

Document Type

Abstract